Cargando…

PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes

Both intermittent fasting and specific probiotics have shown promise in improving glucose tolerance with a potential for synergistic effects through alterations to gut microbiota. In this randomized, double-blinded, two-arm feasibility study, we investigated whether intermittent fasting, supplemente...

Descripción completa

Detalles Bibliográficos
Autores principales: Tay, Audrey, Pringle, Hannah, Penning, Elise, Plank, Lindsay D., Murphy, Rinki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698325/
https://www.ncbi.nlm.nih.gov/pubmed/33212907
http://dx.doi.org/10.3390/nu12113530
_version_ 1783615804710846464
author Tay, Audrey
Pringle, Hannah
Penning, Elise
Plank, Lindsay D.
Murphy, Rinki
author_facet Tay, Audrey
Pringle, Hannah
Penning, Elise
Plank, Lindsay D.
Murphy, Rinki
author_sort Tay, Audrey
collection PubMed
description Both intermittent fasting and specific probiotics have shown promise in improving glucose tolerance with a potential for synergistic effects through alterations to gut microbiota. In this randomized, double-blinded, two-arm feasibility study, we investigated whether intermittent fasting, supplemented with Lacticaseibacillus rhamnosus HN001 probiotic, reduces HbA1c in individuals with prediabetes. All participants with HbA1c 40–50 mmol/mol commenced intermittent fasting (2 days per week of calorie restriction to 600–650 kcal/day) and were randomized 1:1 to either daily probiotic (Lacticaseibacillus rhamnosus HN001) or placebo for 12 weeks. The primary outcome was a change in HbA1c. Secondary outcomes included changes in anthropometry, body composition, glucoregulatory markers, lipids, hunger hormones, liver enzymes, inflammatory markers, gut hormones, calorie and macronutrient intake, quality of life, hunger, mood and eating behavior. Of 33 participants who commenced the trial, 26 participants (mean age 52 years, body mass index (BMI) 34.7 kg/m(2)) completed the intervention (n = 11 placebo, n = 15 probiotic). HbA1c decreased from 43 ± 2.7 mmol/mol to 41 ± 2.3 mmol/mol, p < 0.001, with average of 5% weight loss. No significant between-group differences were seen in primary or secondary outcomes except for social functioning (p = 0.050) and mental health (p = 0.007) scores as improvements were seen in the probiotic group, but not in the placebo group. This study shows additional psychological benefits of probiotic supplementation during intermittent fasting to achieve weight loss and glycemic improvement in prediabetes.
format Online
Article
Text
id pubmed-7698325
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76983252020-11-29 PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes Tay, Audrey Pringle, Hannah Penning, Elise Plank, Lindsay D. Murphy, Rinki Nutrients Article Both intermittent fasting and specific probiotics have shown promise in improving glucose tolerance with a potential for synergistic effects through alterations to gut microbiota. In this randomized, double-blinded, two-arm feasibility study, we investigated whether intermittent fasting, supplemented with Lacticaseibacillus rhamnosus HN001 probiotic, reduces HbA1c in individuals with prediabetes. All participants with HbA1c 40–50 mmol/mol commenced intermittent fasting (2 days per week of calorie restriction to 600–650 kcal/day) and were randomized 1:1 to either daily probiotic (Lacticaseibacillus rhamnosus HN001) or placebo for 12 weeks. The primary outcome was a change in HbA1c. Secondary outcomes included changes in anthropometry, body composition, glucoregulatory markers, lipids, hunger hormones, liver enzymes, inflammatory markers, gut hormones, calorie and macronutrient intake, quality of life, hunger, mood and eating behavior. Of 33 participants who commenced the trial, 26 participants (mean age 52 years, body mass index (BMI) 34.7 kg/m(2)) completed the intervention (n = 11 placebo, n = 15 probiotic). HbA1c decreased from 43 ± 2.7 mmol/mol to 41 ± 2.3 mmol/mol, p < 0.001, with average of 5% weight loss. No significant between-group differences were seen in primary or secondary outcomes except for social functioning (p = 0.050) and mental health (p = 0.007) scores as improvements were seen in the probiotic group, but not in the placebo group. This study shows additional psychological benefits of probiotic supplementation during intermittent fasting to achieve weight loss and glycemic improvement in prediabetes. MDPI 2020-11-17 /pmc/articles/PMC7698325/ /pubmed/33212907 http://dx.doi.org/10.3390/nu12113530 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tay, Audrey
Pringle, Hannah
Penning, Elise
Plank, Lindsay D.
Murphy, Rinki
PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title_full PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title_fullStr PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title_full_unstemmed PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title_short PROFAST: A Randomized Trial Assessing the Effects of Intermittent Fasting and Lacticaseibacillus rhamnosus Probiotic among People with Prediabetes
title_sort profast: a randomized trial assessing the effects of intermittent fasting and lacticaseibacillus rhamnosus probiotic among people with prediabetes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698325/
https://www.ncbi.nlm.nih.gov/pubmed/33212907
http://dx.doi.org/10.3390/nu12113530
work_keys_str_mv AT tayaudrey profastarandomizedtrialassessingtheeffectsofintermittentfastingandlacticaseibacillusrhamnosusprobioticamongpeoplewithprediabetes
AT pringlehannah profastarandomizedtrialassessingtheeffectsofintermittentfastingandlacticaseibacillusrhamnosusprobioticamongpeoplewithprediabetes
AT penningelise profastarandomizedtrialassessingtheeffectsofintermittentfastingandlacticaseibacillusrhamnosusprobioticamongpeoplewithprediabetes
AT planklindsayd profastarandomizedtrialassessingtheeffectsofintermittentfastingandlacticaseibacillusrhamnosusprobioticamongpeoplewithprediabetes
AT murphyrinki profastarandomizedtrialassessingtheeffectsofintermittentfastingandlacticaseibacillusrhamnosusprobioticamongpeoplewithprediabetes